To examine the hypothesis that poorer social and family support, identifiable at the onset of treatment, is associated with nonadherence in the first 6 months of treatment of patients with first-episode psychosis (FEP), independent of other patient-related factors.
N onadherence to treatment, a significant barrier to success in treating various conditions in general medicine and psychiatry, is relatively high in schizophrenia, 1 with rates in FEP reported to be 19%, 44%, and 56% after 3, 6, and 12 months of treatment, respectively. 2, 3 Despite high rates of response to antipsychotic medication in the early phase of psychosis, 4, 5 considerable variation in the level of (partial, compared with complete) and time to remission 4, 5 are influenced significantly by adherence to medication, 7 in addition to other predictors, such as DUP and premorbid adjustment. 5, [8] [9] [10] Poor adherence has also been associated with an increased risk and rate of relapse, 11, 12 increased number of voluntary and involuntary admissions, 13 greater levels of residual positive symptoms, 12 and poor quality of life, 12 social relations, and activities of daily living. 14 Outcome in the early phase of illness may be associated with longer-term global outcome in schizophrenia. 15 Hence, potentially malleable predictors, such as adherence to medication during treatment of FEP, may have important implications for the course of illness. A significant association reported recently between better social-family support and reduced hospitalization 3 years after initial treatment of an FEP 16 may also be mediated through the impact of such support on adherence to medication.
Adherence to medication in later stages of schizophrenia has been studied extensively, but only a few studies have examined factors associated with nonadherence at the time of first treatment. 3, 12, 18, 19 Increased family concern, expressed as visiting the patient and (or) contacting the therapist, 3 but not family involvement in treatment 12 or families' attitudes towards illness and the patient, 18 have been associated with better adherence. It is difficult to draw any firm conclusions based on these few studies because of methodological differences and inconsistencies in the definition of adherence and (or) social and family support used. Further, patients' attitudes about drug treatment 22 at the time treatment is first offered may be particularly important for subsequent adherence, even in the context of social and family support.
Our study's purpose was to prospectively assess which patient-and illness-related factors, identifiable at the onset of treatment, may be associated with nonadherence in the first 6 months of treatment of patients experiencing a FEP. We hypothesized that social and family support has a positive influence on patients' adherence to medication independent of other potential predictors of adherence.
Method

Description of the Study Site
This study was conducted at the PEPP in Montreal, Quebec, a specialized catchment area-based early intervention service for psychotic disorders. Patients are offered antipsychotic medication; a structured family psycho-educational intervention; group interventions directed at improving their social-personal skills and self-efficacy; and cognitivebehavioural therapy in cases with postpsychotic depression-anxiety and residual positive symptoms. Criteria for patients' admission include: aged 14 to 30 years; symptoms meeting criteria for a DSM-IV psychotic disorder; and not in receipt of antipsychotic medication for a period greater than 1 month.
Subjects
As part of the PEPP protocol, which has been approved by the Research Ethics Board of McGill University, patients provide informed consent to participate in regular research follow-up assessments and allow the findings of these assessments to be used for the purposes of research. Subjects included all successive patients admitted to PEPP-Montreal during the first 3 years following the inception of the program. Diagnoses were established using the Structured Clinical Interview for DSM-IV 23 conducted by trained interviewers, typically within the first month of entry to PEPP, followed by consensus between the rater and 2 senior psychiatrists. Patients with a primary diagnosis of substance-induced psychosis were excluded.
Assessments Independent Variables. Demographics and Patient Characteristics.
A semi-structured interview, CORS, 7,24 was administered at the time of entry to the program by a trained rater. CORS provides information on demographic and clinical variables including the age at onset of psychotic symptoms, time of initiation of adequate antipsychotic therapy, and pathways to care. The DUP is defined as the period beginning with the time at onset of psychotic symptoms to the time of adequate treatment with antipsychotics. Adequate treatment was defined as taking medication for a period of 1 month or until significant response, whichever came first. 5 The information from CORS was corroborated via additional interviews with family members, treating psychiatrist, and clinical case managers. Final ratings on DUP were arrived through consensus between the interviewer and 2 senior researcher-clinicians. Based on 20 cases from the same sample as this study, a relatively high degree of agreement was achieved on estimation of DUP between 3 raters (interclass correlation coefficient, ranging from 0.86 to 0.98).
The Premorbid Adjustment Scale 25 was completed based on interviews with patient, family, and clinicians along with case records. Total score, scores on the social and educational domains, and for each period (childhood, early adolescence, and late adolescence) were calculated by adding the scores on all items and dividing by the total possible score. The final score is thus the proportion bound between 0 (best possible) and 1 (worst possible). The Wechsler Adult Intelligence Scale, third edition, 26 was used to obtain full-scale IQ scores.
Symptom Evaluation. Symptoms at baseline were assessed using the Scale for Assessment of Positive Symptoms, 27 the Scale for Assessment of Negative Symptoms, 28 and the Calgary Depression Scale. 29 Insight was assessed using the PANSS, item G12. 30 Parkinsonism and akathisia were evaluated using the Extrapyramidal Rating Scale 31 and the Barnes Akathisia Scale, respectively. 32 Social and Family Support. Case manager-rated social support was assessed using the relevant item of the provider version of the WQOL. 33 This item states: during the last four weeks this person has (check one): 1. been having good relationships with other and receiving support from family and friends; 2. been receiving only moderate support from family and friends; 3. had infrequent support from family and friends or only when absolutely necessary.
This measure was chosen because of the close contact the case managers have with the patient and the family, and we have previously reported this measure to be predictive of future hospitalization in patients with FEP. 33 The analogous item from the Client Version of the WQOL was also examined as a measure of the patient's perspective of social support received. Responses for the items for both measures were dichotomized as either "good support" or "infrequent or moderate support."
Dependent, Outcome Variable. Adherence to Medications.
Medication adherence was evaluated using a formal interview with a trained rater at 4 time points after the baseline evaluation (months 1, 2, 3, and 6) and was quantified based on the percentage of total prescribed doses of medication the patient had taken over the 4 weeks prior to each interview. This assessment was based on information obtained through direct interview as well as records made by individual case managers on each visit, usually once weekly. For each contact, case managers evaluate adherence based on the percentage of medication taken since the last contact and record these values in structured clinical notes. This information was used in combination with the interviews in assigning ratings of adherence for each of the 4 time points. Ratings were done using a 5-point scale of adherence: 0 (0%), 1 (1% to 25%), 2 (26% to 50%), 3 (51% to 75%), and 4 (76% to 100%). This method was highly correlated with pill counting (r = 0.92) on a sample of 51 patients.
Data Analysis
Definition of Treatment Adherence. The mean ratings over the 4 sequential adherence measurements for each patient (rounded to the nearest whole integer) were used for analysis. Patients with a mean rating of 4 (76% to 100%) were considered treatment adherent, and those with a mean rating of less than 4 (75% or lower) were considered treatment nonadherent. This definition is consistent with a definition of adherence outlined in a recent review of adherence studies in schizophrenia 33 and is expected to correct for clinicians' tendency to overestimate medication adherence. 33 Statistical Analysis. All analyses were completed using the Statistical Package for Social Science software (SPSS Inc, Chicago, IL) and SAS PC, version 8 (SAS Inc, Cary, NC). Differences between groups on all baseline measures were examined using 2-tailed t tests or the Mann-Whitney U test. For categorical variables, chi-square tests and 2-sided Fisher exact tests were used where appropriate. Tetrachoric correlation was used to determine the degree of association between case manager ratings and subject ratings of social support. Logistic regression was performed, including all variables determined to be significant (P < 0.05), in univariate analyses.
Results
Among the patients (n = 110) who met criteria for this study and consented to be evaluated, 8 were excluded as they did not have a single follow-up assessment of adherence beyond baseline, owing to refusal either to be treated or to participate in any further research evaluations. Baseline evaluations were completed on average within 0.4 weeks of admission to PEPP (range -4.4 to 3.3 weeks). Some patients (n = 19) had their baseline evaluations done at the time of initial screening assessment, which occurs prior to formal admission into the program and thus have a negative value. Patients were predominantly single (90.2%) and male (69.6%), with a mean age of 22.6 years (median 22.2, SD 3.91, range 14 to 30 years), and presented with a mean DUP of 46.1 weeks (median 16.3, SD 68.53). Most patients (67%) had achieved an education level of high school graduate or higher. At the time of the initial assessment, most patients (n = 84, 82.4%) met diagnostic criteria for schizophrenia spectrum psychoses (schizophrenia 45, schizophreniform 4, schizoaffective 14, psychosis not otherwise specified 17, delusional disorder 3, and brief psychotic disorder 1) and the rest for affective psychosis (n = 18, 17.6%).
During the first 6 months of treatment, 56 patients (54.9%) were adherent, with mean adherence ratings of 4 (76% to 100% of doses taken) and 46 (45.1%) were nonadherent, with mean ratings of 3 or below (75% or less doses taken). The nonadherent group had a mean rating of 1.9 (SD 1.23).
Demographics and Patient Characteristics
Nonadherent patients were more likely to be single (Table 1 ). There were no significant differences observed for sex, age at admission, DUP, premorbid adjustment (total scores), or IQ (Table 1) .
Diagnosis and Severity of Symptoms
No significant differences were observed between schizophrenia spectrum and affective psychosis or in relation to secondary diagnosis of substance abuse between the adherent and the nonadherent groups ( Table 2) . Scores for the disorganization, psychomotor poverty, and reality distortion syndromes were calculated using the ratings of individual symptoms. 34 No significant differences were found regarding the scores for each syndrome or in the levels of depressive symptoms at first assessment ( Table 2) .
Early Medication Refusal, Insight, and Side Effects
Patients in the nonadherent group were more likely to have either rejected taking medication or not taken it as prescribed at the time of first offer of treatment (that is, initial assessment for entry to the program) than the adherent patients (c 2 = 19.70, df = 1, P < 0.001). However, the 2 groups did not differ in terms of level of insight or the proportion of patients experiencing extrapyramidal side effects at initial assessment ( Table 2) . Reliable data on weight gain obtained consistently over the first 2 months following entry to the study were available only for 37 patients. Based on this sample, the difference in the magnitude of weight gained by patients who were adherent (mean gain 7.16 lbs, SD 10.93) and those who were nonadherent (mean 10.37 lbs, SD 9.94) were not statistically significant (t = 0.933, df = 35, P = 0.35).
Social and Family Support
Nonadherent patients were less likely to have received a good level of social support as rated by their case managers, compared to the adherent group (c 2 = 5.89, df = 1, P = 0.02) ( Table  2 ). These evaluations were typically done within a 3-month period after initial presentation. Based on the patients' own ratings of family and social support, available for a smaller sample of 58, the difference reported for adherence to medication using case managers' ratings was not replicated. Using tetrachoric correlation, no association was found between case managers' and patients' ratings (rho = 0.27, SE = 0.21) for those cases where data for both were available (n = 53).
Logistic Regression
Logistic regression was performed using early acceptancerefusal to take medication, social support (case manager's perspective), and marital status with adherence as the dependant variable. All 3 variables were entered together in the same model. Both social support (case managers' rating) (OR = 3.552, SE = 0.584, P = 0.03) and early medication acceptance (OR = 11.092, SE = 0.731, P = 0.001) were significant in the regression model (Table 3. ).
Discussion
Nearly one-half of the patients were nonadherent to medications in the first 6 months of treatment using a relatively conservative definition consistent with what has been suggested in the literature. 1 This rate of nonadherence is comparable with that obtained in other FEP samples 13 and confirms the magnitude of this problem. The rate of nonadherence reported here is relatively high for patients who were receiving specialized care and may reflect the very early phase of treatment when issues of engagement and acceptance of treatment are still being negotiated. Such early nonadherence has been shown to significantly influence rate and time to remission even in specialized early intervention services. 7 It is likely these rates improve after the first 6 months, later in the course of treatment.
The main finding of this study was that, in addition to initial refusal to accept medication, not receiving a high level of social support from family and friends confers an increased risk of poor adherence over the first 6 months of treatment.
Patients' own assessment of the quality of support they received was, however, not associated with adherence to medication. This discrepancy may result from the fact that these latter data were based on a much smaller sample. However, based on the lack of correlation between these 2 methods of measurement of social and family support, one can conclude that they represent different perspectives. It is possible that when a case manager observes a parent, family member, or close friend facilitating a patient's medication taking he or she may regard this as providing good support; however, the patient may view these same acts as being unsupportive of them and their own beliefs about the lack of utility of, or even perceived harm caused by, the medication. Being single and having poor social support may also imply that these patients did not have as many people around them who were directly affected by their illness. Witnessing the stressful and disruptive effects that psychotic illness has on those around the patient may also serve to reinforce the need for treatment. The significant role played in help seeking by family members 24 in this patient population would support this contention.
The effect of social support on adherence has been demonstrated in studies involving both chronic schizophrenia 1,36 and FEP. 12 Although our study did not examine symptomatic and functional outcomes, it has been demonstrated that in FEP, family and social support in itself is a strong predictor of the level of positive symptoms and rehospitalization over several years following treatment of FEP, independent of age of onset, sex, and premorbid adjustment. 16 Part of this effect may be mediated through adherence. Further efforts at improving family involvement and other psychosocial interventions may bring about a positive change in patient's attitude toward medication over time.
The fact that patients who were nonadherent over the 6 months were more likely to have refused medications from the onset of the treatment is consistent with the common clinical impression that early attitudes toward medications are likely to persist throughout treatment. Interventions directed at improving motivation early in the course of treatment to take medication need to be explored in future.
We failed to observe previously reported association between adherence and insight into illness 1, 3, 12, 21 and (or) a history of current or past substance use disorder. 1, 12 Our measure of insight based on one item on the PANSS may be too limited to detect differences for the various domains of insight. We also failed to find any association between nonadherence and extrapyramidal side effects. Extrapyramidal side effects from antipsychotic medications were rather infrequent at the time of entry in the study as expected with the almost exclusive use of novel antipsychotic drugs and relatively short exposure (ranging from 0 to 30 days). An examination of the entire 6 months revealed that few patients experienced any extrapyramidal symptoms that would be considered clinically significant and that there was no difference between the adherent and nonadherent groups in this respect. Differences in adherence to medication observed between patients who do or do not gain weight may have failed to reach significance owing to the relatively small number of subjects on whom reliable data were available during the first 2 months of treatment when significant weight gain has been reported to occur 37 and is most likely to influence the subsequent continuation of medication.
Interpretation of these results may be limited by the difficulty in reliably ascertaining adherence in the absence of pill counting and assays, although the latter are difficult to implement properly and their validity is debatable. 38 It is widely recognized that there is no gold standard for reliably measuring adherence to medication and that concurrent use of multiple measures may increase accuracy of assessment. 38 However, we used different sources of information regarding adherence, applied a relatively conservative criterion, and used multiple observations to arrive at a mean rating. We also reported that our method is highly correlated with pill counting. The relatively brief measure of social support used may be an additional limitation. The generalizability of our results is, however, strengthened by the fact that these results are based on consecutive patients with a diagnosis of FEP who were representative of an epidemiologic sample within a defined catchment area, had minimal prior exposure to medication, and had been extremely well characterized on several other dimensions.
In conclusion, our results provide some preliminary evidence of the significance of social and family support in achieving adherence to medications early in the treatment of an FEP in addition to the influence of early acceptance or rejection of medication. If replicated in a larger prospective study with additional measures of adherence and a more detailed measure of social support, improving adherence to medication may be possible through interventions that facilitate family and social support and those that influence motivation to accept treatment.
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Résumé : Les prédicteurs précoces de la non-observance du traitement antipsychotique dans le premier épisode psychotique
Objectif : Examiner l'hypothèse selon laquelle un mauvais soutien social et familial, identifiable au début du traitement, est associé à la non-observance dans les 6 premiers mois du traitement des patients au premier épisode psychotique (PEP), indépendamment des autres facteurs liés au patient.
Méthode : Des patients consécutifs (n = 100) admis dans un service spécialisé d'intervention précoce du PEP, qui satisfaisaient aux critères de la 4 e édition du Manuel diagnostique et statistique des troubles mentaux pour un trouble du spectre de la schizophrénie ou une psychose affective, ont été évalués chaque mois pendant 6 mois en ce qui concerne leur observance des médicaments. Utilisant les facteurs sociodémographiques et liés à la maladie, y compris le soutien social et familial, comme variables indépendantes et l'observance comme variable dépendante, des analyses univariées ont été suivies de régression logistique.
Résultats :
Cinquante-six patients (54,9 %) étaient observants (76 % à 100 % des doses prises) et 46 (45,1 %) étaient non observants (moins de 76 % des doses prises). Les patients non observants étaient moins susceptibles d'avoir reçu un bon niveau de soutien social (c 2 = 5,89, dl = 1, P = 0,02), tel que coté par leur gestionnaire de cas respectif, et étaient plus susceptibles d'être célibataires (méthode exacte de Fisher, P = 0,019) et d'avoir refusé les médicaments à la première offre du traitement (c 2 = 19,70, dl = 1, P = 0,001). À l'aide de la régression logistique, tant le niveau de soutien social (OR = 3,552, P = 0,03) que l'acceptation précoce des médicaments (OR = 11,092, P < 0,001) étaient significatifs comme prédicteurs de l'observance.
Conclusion :
Ces résultats suggèrent l'importance du soutien social et familial pour réaliser l'observance des médicaments très tôt dans l'évolution du traitement du PEP, outre l'influence de l'acceptation ou du refus précoce des médicaments.
